Interviews

Denise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the role of Afinitor (everolimus) in breast cancer and the BOLERO trials.

Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.

Harvey I. Pass, MD, discusses some of the challenges of treating patients with mesothelioma

Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses the overdiagnosis of breast cancer.

Karl Lewis, MD, discusses new and emerging treatments for metastatic melanoma.

Heather Wakelee, MD, discusses the results of the AVAPERL trial.

Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute, discusses the FDA approval process for oncology drugs.

Anthony M. Magliocco, MD, discusses the difficulties of analyzing the genome of melanoma tumors.

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.

Roy S. Herbst, MD, PhD, discusses targeting PD-1 and PD-L1 when treating patients with lung cancer.

Jeffrey A. Sosman, MD, discusses how immunotherapies work in patients with melanoma or renal cancer.

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.

Debu Tripathy, MD, discusses targeting HER2 in breast cancer.

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Jennifer Woyach, MD, discusses peripheral lymphocytosis in patients with chronic lymphocytic leukemia (CLL) following treatment with ibrutinib.

Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses the background and results of a study looking at crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).

Heather Wakelee, MD, discusses maintenance therapy for patients with lung cancer.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses the efficacy of ipilimumab for the treatment of melanoma.

S. Gail Eckhardt, MD, discusses the role of angiogenesis inhibitors for the treatment of metastatic colorectal cancer (mCRC), following the approval of aflibercept.

Jonathan D. Herman, MD, obstetrician and gynecologist at Hofstra North Shore - LIJ Medical School, discusses the findings from a survey looking at breast cancer risk perception.

Sandra Swain, MD, discusses pregnancy-related breast cancer.

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Julie R. Brahmer, MD, discusses tumor vaccines for patients with lung cancer.

Don S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an update on targeted therapies for the treatment of patients with ovarian cancer.

Harvey I. Pass, MD, discusses blood-based markers in lung cancer.

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

Jennifer Woyach, MD, discusses the benefit of a combination therapy with ibrutinib for patients with chronic lymphocytic leukemia (CLL).

Carol Bush, BS, RN, discusses the role of oncology nurse navigators in healthcare reform.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, discusses the background of the prophage G-200 vaccine for recurrent glioblastoma multiforme.

Andre Goy, MD, discusses the expanded approval of lenalidomide (Revlimid)for patients with relapsed or refractory mantle cell lymphoma (MCL)